In an development for cancer research, the National Cancer Institute's Surgery Branch is reaching out to potential partners in the pharmaceutical industry. Their goal? To combine cutting-edge vaccine technology with advanced cell therapy techniques in the fight against cancer.
The Collaboration
The NCI Surgery Branch, led by the renowned Dr. Steven Rosenberg, is looking for a partner capable of producing a GMP-grade vaccine targeting cancer neo-antigens. This vaccine would work in tandem with engineered T cells developed using the NCI's proprietary methods.
The ultimate aim is to conduct a Phase I clinical trial for solid cancers, potentially paving the way for more effective treatments for patients with advanced forms of the disease.
What NCI Brings to the Table
Expertise in TIL and TCR-transduced PBL development
Ability to provide GMP-Grade TILs or PBLs
Patient recruitment and trial conduction at NCI facilities
The Ideal Partner
The NCI is seeking an industry collaborator with expertise in vaccine manufacture. This partner would be responsible for providing the GMP-grade vaccine to be used alongside the NCI's engineered T cells.
About Dr. Steven Rosenberg
Dr. Rosenberg, Chief of the Surgery Branch at NCI's Center for Cancer Research, is a pioneer in cancer immunotherapy. His groundbreaking work has led to durable complete remissions in patients with advanced solid cancers. Dr. Rosenberg's current research focuses on understanding and harnessing the host immune response to cancer.
Moving Forward
This collaboration represents a significant opportunity to advance cancer treatment. Interested companies can contact Aida Cremesti, Senior Technology Transfer Manager at the NCI Technology Transfer Center, for more information.
For more details on this partnership opportunity, visit: NCI Technology Transfer Center
Stay curious, stay informed, and stay tuned to OniX OnPoint!
We look forward to your feedback - please share your thoughts and don't forget to subscribe to the OniX OnPoint Newsletter to stay updated on the latest biomedical innovations.
Comments